Development of next-generation designer cell with improved adipose-derived stem cells (ADSCs)

While suppressing inflammation and promoting neural regeneration are key to improving the prognosis of ischemic stroke, the effectiveness of existing treatments and mesenchymal stem cell transplantation is limited. Recent reports have revealed significant individual variation in the therapeutic efficacy and cytokine secretion capacity of ADSCs. We have determined that differences in the expression levels of HGF (hepatocyte growth factor), secreted by ADSCs, determine the therapeutic efficacy in models of ischemic stroke and autoimmune diseases. Based on these findings, we are currently advancing the development of high-performance engineered ADSCs through genetic modification designed to enhance HGF expression and improve their ability to migrate to the site of the lesion. We aim to establish next-generation regenerative medicine that overcomes individual variability and maximizes therapeutic potential, while also pursuing the discovery of novel therapeutic target molecules.